Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was
still primarily topical corticosteroids and, for more severe disease, systemic …

Objective To discuss the efficacy and safety of novel and emerging topical and systemic
therapeutic agents for atopic dermatitis (AD). Data Sources The review of the published …

Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown
notable progress. An increasing number of aspects of the immune system are being …

Introduction: Atopic dermatitis (AD) is a heterogeneous disease. Recent advancements in
understanding AD pathogenesis resulted in the exponential expansion of its therapeutic …

Objective Atopic dermatitis (AD) is an increasingly common inflammatory skin disease
undergoing significant revolution in recent years. New data on disease pathogenesis …

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that
affects children and adults. Until recently, the only Food and Drug Administration–approved …

Atopic dermatitis (AD) is an inflammatory skin disease arising from a complex interplay of
genetic, immune, and environmental factors. The development and successful marketing of …

The last decade has seen an unprecedented pace of change, particularly of clinical
research in atopic dermatitis (AD). This review summarizes some key discoveries. Over the …

Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is
characterized by persistent itch and marked redness. AD is associated with an increased …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …